Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | DBH | P09172 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16411029 | 0.86 | HTR2A (0.39) | HTR2AHTR2CHTR2BDBHTAAR1 | |
| SCHEMBL10480330 | 0.81 | HTR2A (0.50) | HTR2AHTR2CHTR2BDBHTAAR1 | |
| SCHEMBL4547651 | 0.79 | PTGS2 (0.58) | HTR2AHTR2CHTR2BDBHPTGS2 | |
| SCHEMBL507505 | 0.78 | HTR2A (0.46) | HTR2AHTR2CHTR2BLOXL2LOX | |
| SCHEMBL24088153 | 0.77 | DBH (0.44) | HTR2AHTR2CHTR2BDBHTAAR1 | |
| SCHEMBL3769931 | 0.77 | DBH (0.44) | HTR2AHTR2CHTR2BDBHPTGS2 | |
| SCHEMBL3764427 | 0.77 | MAPT (0.50) | HTR2AHTR2CHTR2BDBHPTGS2 | |
| SCHEMBL22516438 | 0.77 | DBH (0.44) | HTR2AHTR2CHTR2BDBHTAAR1 | |
| SCHEMBL28091715 | 0.77 | DBH (0.44) | HTR2AHTR2CHTR2BDBHTAAR1 | |
| SCHEMBL13548271 | 0.76 | HTR2A (0.44) | HTR2AHTR2CHTR2BDBHTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-9605022-B2 | Macrocyclic compounds for inhibition of inhibitors of apoptosis | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605022-B2 | Macrocyclic compounds for inhibition of inhibitors of apoptosis | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605022-B2 | Macrocyclic compounds for inhibition of inhibitors of apoptosis | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2776409-B1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS CORP (US) | 2016-02-03 | — | — | EP | disclosed |
| US-20150284427-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284427-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284427-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
| EP-0190817-B1 | DOPAMINE-BETA-HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-09-05 | — | — | EP | disclosed |
| US-4857540-A | 1-SUBSTITUTED-2-MERCAPTO-(OR AMINOMETHYL-)BENZAMIDAZOLE COMPOUNDS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-08-15 | — | — | US | disclosed |
| WO-1989006125-A1 | 4-ARALKYL-5-SUBSTITUTED-1,2,4-TRIAZOLE-5-THIOLS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0323737-A1 | 4-Aralkyl-5-substituted-1,2,4-triazole-5-thiols | SMITHKLINE BEECHAM CORPORATION (US) | 1989-07-12 | — | — | EP | disclosed |
| US-4728741-A | DOPAMINE BETA-HYDROXYLASE INHIBITOR | SMITHKLINE BECKMAN CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0225718-A2 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1987-06-16 | — | — | EP | disclosed |
| US-4628059-A | TRIAZOLES | SMITHKLEIN BECKMAN CORPORATION (US) | 1986-12-09 | — | — | US | disclosed |
| EP-0190817-A1 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | HTR2A 2736/4885HTR2C 2879/4885HTR2B 4162/4885 |
| US-20150284427-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BAX, API5, BCL2 | HTR2A 4121/4885HTR2C 4459/4885HTR2B 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.